{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:52Z","timestamp":1793196592238,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00228-023-03521-4","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T20:08:12Z","timestamp":1687378092000},"page":"1023-1029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Review of the clinical development of fexuprazan for gastroesophageal reflux\u2013related disease"],"prefix":"10.1007","volume":"79","author":[{"given":"Azaan","family":"Ramani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks D.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"issue":"1","key":"3521_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH et al (2022) ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 117(1):27\u201356","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3521_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","volume":"67","author":"LH Eusebi","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Yuan Y et al (2018) Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 67(3):430\u2013440","journal-title":"Gut"},{"issue":"26","key":"3521_CR3","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3748\/wjg.v11.i26.4067","volume":"11","author":"WH Wang","year":"2005","unstructured":"Wang WH, Huang JQ, Zheng GF et al (2005) Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 11(26):4067\u20134077","journal-title":"World J Gastroenterol"},{"key":"3521_CR4","unstructured":"Khan M, Santana J, Donnellan C et al (2007) Medical treatments in the short term management of reflux oesophagitis.\u00a0Cochrane Database Syst Rev (2):CD003244. Published 2007 Apr 18"},{"issue":"4","key":"3521_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1592\/phco.23.4.460.32128","volume":"23","author":"E Chong","year":"2003","unstructured":"Chong E, Ensom MH (2003) Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23(4):460\u2013471","journal-title":"Pharmacotherapy"},{"issue":"3","key":"3521_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","volume":"96","author":"JE Richter","year":"2001","unstructured":"Richter JE, Kahrilas PJ, Johanson J et al (2001) Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 96(3):656\u2013665","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3521_CR7","first-page":"98","volume":"8","author":"DA Johnson","year":"2008","unstructured":"Johnson DA, Katz PO (2008) Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord 8(2):98\u2013108","journal-title":"Rev Gastroenterol Disord"},{"key":"3521_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1572-0241.1998.221_a.x","volume":"93","author":"PL Peghini","year":"1998","unstructured":"Peghini PL, Katz PO, Bracy NA et al (1998) Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763\u2013767","journal-title":"Am J Gastroenterol"},{"key":"3521_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1046\/j.1365-2036.1999.00641.x","volume":"13","author":"YM Fouad","year":"1999","unstructured":"Fouad YM, Katz PO, Castell DO (1999) Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 13:1467\u20131471","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3521_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1053\/gast.2002.31876","volume":"122","author":"WK Fackler","year":"2002","unstructured":"Fackler WK, Ours TM, Vaezi MF (2002) Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122(3):625\u2013632","journal-title":"Gastroenterology"},{"key":"3521_CR11","doi-asserted-by":"crossref","unstructured":"Hunt RH, Scarpignato C (2015) Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease?\u00a0Clin Transl Gastroenterol 6(10):e119. Published 2015 Oct 29","DOI":"10.1038\/ctg.2015.39"},{"issue":"7","key":"3521_CR12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.16295","volume":"53","author":"Y Abdel-Aziz","year":"2021","unstructured":"Abdel-Aziz Y, Metz DC, Howden CW (2021) Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther 53(7):794\u2013809","journal-title":"Aliment Pharmacol Ther"},{"key":"3521_CR13","unstructured":"Ministry of Food and Drug Safety (2022) South Korean 2021 drug approval report. Government Publications. Registration number 11\u20131471057\u2013000120\u201310"},{"key":"3521_CR14","doi-asserted-by":"crossref","unstructured":"Sugano K (2018) Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.\u00a0Ther Adv Gastroenterol 11:1756283X17745776. Published 2018 Jan 9","DOI":"10.1177\/1756283X17745776"},{"key":"3521_CR15","doi-asserted-by":"crossref","unstructured":"Kim MS, Lee N, Lee A et al (2022) Model-based prediction of acid suppression and proposal of a new dosing regimen of fexuprazan in humans.\u00a0Pharmaceuticals (Basel) 15(6):709. Published 2022 Jun 3","DOI":"10.3390\/ph15060709"},{"issue":"2","key":"3521_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/apt.14818","volume":"48","author":"J Sunwoo","year":"2018","unstructured":"Sunwoo J, Oh J, Moon SJ et al (2018) Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 48(2):206\u2013218","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3521_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H et al (2015) Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther 42(6):719\u2013730","journal-title":"Aliment Pharmacol Ther"},{"issue":"11\u201312","key":"3521_CR18","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/apt.16131","volume":"52","author":"JG Hwang","year":"2020","unstructured":"Hwang JG, Jeon I, Park SA et al (2020) Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities. Aliment Pharmacol Ther 52(11\u201312):1648\u20131657","journal-title":"Aliment Pharmacol Ther"},{"issue":"44","key":"3521_CR19","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3748\/wjg.v28.i44.6294","volume":"28","author":"KN Lee","year":"2022","unstructured":"Lee KN, Lee OY, Chun HJ et al (2022) Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol 28(44):6294\u20136309","journal-title":"World J Gastroenterol"},{"issue":"7 Suppl","key":"3521_CR20","first-page":"Su1311","volume":"164","author":"I-K Sung","year":"2023","unstructured":"Sung I-K, Lee OY, Choi M-G et al (2023) Randomized, double-blind, multicenter study to evaluate the efficacy and safety of dwp14012 (fexuprazan) according to the timing of dosing in patients with erosive esophagitis. Gastroenterology 164(7 Suppl):Su1311","journal-title":"Gastroenterology"},{"issue":"7Suppl","key":"3521_CR21","first-page":"Su1303","volume":"164","author":"SY Moon","year":"2023","unstructured":"Moon SY, Xiao Y (2023) A phase 3, non-inferiority randomized controlled trial with fexuprazan, a novel potassium-competitive acid blocker vs. esomeprazole in Chinese patients with erosive esophagitis. Gastroenterology 164(7Suppl):Su1303","journal-title":"Gastroenterology"},{"key":"3521_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/apt.13324","volume":"42","author":"L Lundell","year":"2015","unstructured":"Lundell L, Vieth M, Gibson F et al (2015) Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 42:649\u2013663","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3521_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T et al (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43(2):240\u2013251","journal-title":"Aliment Pharmacol Ther"},{"key":"3521_CR24","unstructured":"Cochrane Library (2023) Search | Cochrane Library. https:\/\/www.cochranelibrary.com\/search. Accessed 15 Jan 2023"},{"key":"3521_CR25","unstructured":"Moon-hee C (2022) Daewoong applies for Fexuclue approval in 10 countries. BusinessKorea. http:\/\/www.businesskorea.co.kr\/news\/articleView.html?idxno=105999. Accessed 15 Jan 2023"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03521-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T08:29:53Z","timestamp":1702628993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3521"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03521-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"10 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}